This bill requires Pennsylvania to align its scheduling of synthetic psilocybin with federal changes. Specifically, it mandates that after the U.S. Food and Drug Administration approves a federal scheduling change for synthetic psilocybin, the Pennsylvania Secretary of Health must schedule it within five business days and the change takes effect 30 days after publication in the Pennsylvania Bulletin. The law directly affects state health authorities and regulatory processes, ensuring Pennsylvania’s rules mirror federal actions without creating new medical uses or penalties. It does not alter current state restrictions but establishes a procedural mechanism for future alignment.
SB 1126 requires most health insurance plans in Pennsylvania to cover at least two epinephrine delivery systems (such as EpiPens for severe allergic reactions) per year at a maximum annual cost of $35, regardless of the insured's deductible or other cost-sharing. This applies to individual and group health insurance policies, as well as certain nonprofit health plans. The Attorney General must investigate epinephrine drug pricing and submit a public report to the legislature within one year. The bill also allows plans to reduce cost-sharing below $35 and applies to high deductible and catastrophic health plans where permitted by federal law.
HB 2110 repeals existing restrictions on using public funds for abortions under Pennsylvania's Human Services Code. It removes Section 453, which previously limited state/local government funding for abortions except in cases of life endangerment, rape, or incest (with reporting requirements). The bill also abrogates a related regulation (55 Pa. Code § 1163.62(a)). This change directly affects public assistance programs and healthcare providers receiving state funds, eliminating the prior legal barriers to funding abortion services. The policy shift removes specific restrictions but does not establish new funding rules for public assistance programs.
HB 2182 amends Pennsylvania's Controlled Substance Act to allow emergency medical services (EMS) providers to administer opioid overdose medications, specifically naloxone and nalmefene, as part of their standard practice. The bill requires the Department of Health to update EMS provider regulations to include these medications within their scope of practice. This change directly affects EMS personnel by enabling them to respond to opioid overdoses more effectively without needing additional authorization during emergencies. The bill takes effect 60 days after enactment.
HB 2111 amends Pennsylvania's abortion laws to restrict public facilities and funds. It prohibits publicly owned hospitals, clinics, or government entities from leasing property, entering contracts, or using public funds to support abortion services - except for cases where abortion is necessary to save a mother's life, or to terminate pregnancies resulting from rape or incest that have been reported to law enforcement (with specific documentation requirements). The bill also bans public funds from being used for legal services related to abortion access or restrictions, and requires strict verification of rape/incest reports before funding can be approved for those exceptions. These changes directly affect public health facilities, government agencies, and providers receiving public funding.
HB 1628 extends Pennsylvania's medical assistance program to cover pregnancy-related care and postpartum support for up to 12 additional months after childbirth or pregnancy loss (such as miscarriage). It directly affects pregnant and postpartum women who are currently receiving medical assistance, have income below 215% of the federal poverty level, and are not otherwise eligible for ongoing assistance. The bill requires the state to seek federal approval for this extension via a waiver under the Social Security Act, and if federal approval is denied, it mandates a report to the legislature within 180 days detailing how to revise the application for future approval. This change aims to improve access to healthcare during a critical period following pregnancy.
This bill (SB 1122) requires most health insurance policies sold in Pennsylvania to cover menopause treatment. Specifically, it mandates coverage for FDA-approved drugs, behavioral therapy, and post-hysterectomy menopause treatments under Section 635.11 of the Insurance Company Law. The requirement applies to standard health insurance policies (excluding dental, vision, workers' compensation, and similar limited-benefit plans) and takes effect 60 days after enactment, with most policies needing to comply within 180 days of the effective date. It does not alter existing cost-sharing rules like deductibles or copays.
HB 2175 requires businesses using AI chatbots to clearly disclose when consumers are interacting with artificial intelligence, especially for mental health support (e.g., chatbots claiming to treat anxiety or depression). It prohibits deceptive advertising, mandates protection of personal data shared with these tools, and gives Pennsylvania’s Attorney General’s Bureau of Consumer Protection authority to enforce these rules and impose penalties. The law directly affects companies offering AI chatbots that provide health-related advice to Pennsylvania residents. It does not cover scripted tools (like guided meditation) or AI that simply connects users with human professionals.
HB 2181 amends Pennsylvania's Controlled Substance Act to define "opioid antagonist" as drugs approved by the U.S. Food and Drug Administration for emergency reversal of opioid overdoses, including naloxone hydrochloride and similar FDA-approved medications. The bill specifically adds these examples to the legal definition within the existing law. This change directly affects healthcare providers, emergency responders, and pharmacists who administer these medications during opioid overdose emergencies by clarifying the legal scope of approved treatments.
HB 2096 establishes a legal framework for direct primary care in Pennsylvania, allowing physicians to provide routine health services (like preventive care and chronic condition management) through written agreements with patients in exchange for a direct fee (e.g., monthly membership or retainer). These medical service agreements are explicitly exempt from state insurance regulations and must clearly state they do not provide comprehensive health insurance coverage. Patients may use health savings accounts or flexible spending accounts to pay for these agreements, subject to federal and state rules. The bill requires all agreements to be in writing, specify covered services and fees, allow termination with notice, and include the required disclaimer.
